Introduction {#s1}
============

The perinatal and the postpartum period are critical time-windows for women because of the changes in their physiology, social situation, and psychological well-being, all of which influences sleep quality ([@B1]). Sleep problems, such as poor sleep quality and sleep disturbance, often occur in perinatal and postnatal women. For instance, 14--76% of expectant mothers experience clinically significant insomnia symptoms ([@B2], [@B3]), while the figure increases up to 87.5% in postpartum women ([@B4]). The wide- ranging prevalence across studies are partly due to different sample demographic characteristics, sampling methods, and assessment tools. In addition, the definition of the perinatal period is inconsistent, which leads to bias due to exposure misclassification. It usually refers to the period before and after delivery, which usually begins at the 20^th^ to 28^th^ week of gestation and ends 1 to 4 weeks after childbirth ([@B5]). Some researchers even classify the perinatal period as the whole pregnancy and 1 year postpartum ([@B6]). In China, perinatal time is defined as the period that starts at the 28^th^ week of pregnancy and ends 1 week after delivery ([@B7]).

Women experience changes in sleep patterns and increased levels of tiredness after childbirth ([@B8]). For example, postnatal women usually sleep less and worse during the early days following child delivery than during pregnancy and/or other time periods of reproductive age ([@B9]). Consequently, after delivery, women often reported more daytime napping, decreased total sleep time, and poorer sleep efficiency compared with late pregnancy ([@B10]), all of which affects sleep quality. In addition, some demographic and clinical characteristics are significantly associated with poor sleep quality ([@B11], [@B12]). For perinatal women, advanced maternal age, fluid retention, anemia, discomfort (e.g., uncomfortable sleeping positions), and body pain, as well as mood disturbance (e.g., depressive symptoms), were correlates of sleep disturbances and quality ([@B13]--[@B15]). As for postnatal new mothers, family/social support, postpartum stress, demands from the infant (i.e., nighttime feeding and care), physical changes, and bed sharing/sleeping with the infant affects sleep quality ([@B16]--[@B18]). In addition, parity was another potential factor, as multipara women usually have less efficient sleep than nulliparas women from prepregnancy until 3 months postpartum ([@B19]). Moreover, compared to vaginal deliveries, caesarean sections were associated with poorer sleep quality and more frequent nighttime awakenings ([@B20]). Poor sleep quality could lead to negative physical and mental health outcomes ([@B21]). For example, poor sleep quality in pregnancy may increase the chances of preterm birth and longer labor ([@B22], [@B23]) and increase the risk of depression and suicidal ideation during pregnancy and the postnatal period ([@B6], [@B24]).

In order to allocate health resources and reduce the negative impact of poor sleep quality on health outcomes, it is important to understand its pattern and associated factors. Some studies have examined the prevalence of poor sleep quality, but the findings were mixed. Sedov et al. ([@B1]) conducted a meta-analysis of sleep quality during pregnancy and found that 45.7% of pregnant women experienced poor sleep quality and gestational age was a moderating factor. However, postpartum women were excluded, and only English databases were searched, restricting the generalizability of the findings.

Sleep quality, defined as an individual\'s subjective perception about his or her sleep ([@B25]), could be measured by both objective \[e.g., polysomnography (PSG) and actigraphy ([@B25])\] and subjective methods \[e.g., sleep diary and standardized instruments, such as the Pittsburgh Sleep Quality Index (PSQI)\]. The PSQI is a widely used questionnaire on sleep quality in the past month ([@B26]). It has been translated and validated in many populations, such as in Chinese ([@B27]), Japanese ([@B28]), Korean ([@B29]), French ([@B30]), Kurdish ([@B31]), Portuguese ([@B32]), Serbian ([@B33]), Hungarian ([@B34]), and Persian ([@B35]). The psychometric properties of the PSQI--Chinese version is satisfactory, with the Cronbach\'s alpha of 0.734 ([@B27]). The PSQI total score ranges from 0 to 21, with higher scores indicating poorer sleep quality. The most commonly used cut-off value for poor sleep quality is 5 ([@B26]).

Study aim {#s1_1}
---------

The aim of this meta-analysis was to examine the prevalence of poor sleep quality in perinatal and postpartum women and investigate its associated moderators. Following previous meta-analysis and empirical studies ([@B1], [@B36], [@B37]), associated moderators of poor sleep quality in perinatal and postpartum women were preidentified. In order to reduce heterogeneity caused by different measures, only studies using PSQI were included.

Methods {#s2}
=======

Literature Search {#s2_1}
-----------------

This meta-analysis was conducted according to the guidance of the preferred reporting items for systematic reviews and meta-analyses (PRISMA). Three investigators (YY, WL, TJM) independently and systematically conducted a literature search in PubMed, EMBASE, PsycINFO, Web of Science, CNKI, and Wangfang from their inception dates until 28th March 2019, using the following search words: (postpartum, postnatal, perinatal, maternal, Pittsburgh Sleep Quality Index, and PSQI. The PROSPERO registration number of this study is: CRD42019139366.

Study Criteria {#s2_2}
--------------

Following previous studies ([@B38], [@B39]), the perinatal period was defined as occurring from the 28^th^ week of gestation to 1 week postnatal, and the postpartum period was defined as occurring from the 2^nd^ week postnatal to 1 year. Original studies that fulfilled the following criteria were included: (1) papers published in English or Chinese; (2) cross-sectional, longitudinal, or cohort studies (only baseline data of cohort studies were extracted); (3) focusing on perinatal and/or postpartum women; (4) reporting data on sleep quality as measured by PSQI; (5) having data on PSQI score or the prevalence of poor sleep quality, or relevant data that could generate the prevalence of poor sleep quality. Articles including perinatal and/or postpartum women with severe sleep problems, such as restless legs syndrome (RLS) or obstructive sleep apnea (OSA), were excluded as their inclusion may lead to significant selection bias and an overestimation of the prevalence of poor sleep quality.

Data Extraction and Quality Assessment {#s2_3}
--------------------------------------

After duplicates were removed, the same three investigators independently screened all titles and abstracts of relevant publications and then reviewed all full texts for eligibility. Relevant data were extracted using a standardized data collection sheet, such as the first author, publication year, study design, location, sample size, mean age, depressive/anxiety status, comorbidities, PSQI cut-off value, PSQI score, and prevalence of poor sleep quality. Any disagreement was discussed and resolved by a consultation with a senior investigator (YTX).

Quality assessment was conducted by the same three authors independently using Parker\'s quality evaluation tool for epidemiological studies ([@B40]), with six domains: definition of the target population, representativeness of the study sample, sampling method, response rate, definition of the target symptom or diagnosis, and validation of the assessment instrument.

Statistical Analyses {#s2_4}
--------------------

Comprehensive Meta-Analysis Program 2.0 (CMA 2.0, <http://www.meta-analysis.com/>) was used to analyze data. Considering various sampling methods and sample size across studies, the random-effects model was utilized in all analyses. Heterogeneity was tested by the Q and *I* ^2^ statistics (an *I* ^2^ of \> 50% or a *P* value of \< 0.10 was considered as significant heterogeneity) ([@B41]). In order to explore potential sources of heterogeneity, we conducted subgroup, meta-regression, and sensitivity analyses according to the following variables ([@B42]): continent, study site (multicenter vs. single site), hospital type (general vs. specialized), publication year (categorized by median splitting method), PSQI cut-off, maternal age, survey year, and quality assessment score. Publication bias was assessed using funnel plot and the Begg\'s regression model ([@B43]). Statistical significance in this study was set at *P* \< 0.05 (two-tailed).

Results {#s3}
=======

Literature Search and Study Characteristics {#s3_1}
-------------------------------------------

The PRISMA flowchart of literature search and selection is shown in [**Figure 1**](#f1){ref-type="fig"}. Altogether, 1,249 relevant articles were identified. Of them, 777 were excluded by reviewing titles and abstracts. After full texts were read for eligibility, 42 studies covering 12,592 individuals were included for analyses. Of them, 28 studies reported prevalence of poor sleep quality in perinatal women, 12 reported data in postnatal women, and 2 studies included both the populations. [**Table 1**](#T1){ref-type="table"} displays the characteristics of the included studies. The total sample size varied from 30 to 2,830. Most of the studies were conducted in Asia (n = 36), followed by Europe (n = 4), and North America (n = 2). More than half (n = 23) of the studies were conducted in one study site, and half (n = 21) recruited patients without physical comorbidities (i.e., pregnancy hypertension, heart disease, or diabetes). Twenty studies reported data of depressive symptoms, and five reported percentage of anxiety symptoms. Seven studies utilized the Center for Epidemiologic Studies Depression Scale (CES-D) to assess participant\'s depressive symptoms, seven used Edinburgh Postnatal Depression Scale (EPDS), four used Self-Rating Depression Scale (SDS), while the remaining two used Hospital Anxiety and Depression Scale (HADS). Regarding anxiety symptoms, three studies utilized the Self-Rating Anxiety Scale (SAS), and two used HADS. The percentage of participants with depressive symptoms ranged from 8.4 to 57.3%, while the corresponding figure for anxiety symptoms ranged from 18.3 to 29.4%.

![PRISMA Flowchart.](fpsyt-11-00161-g001){#f1}

###### 

Characteristics of the included studies.

  No   First author (year)   Ref        Country      Sampling method      N       Pregnancy stage   Primipara   Physical comorbidity   Age (M ± SD)   BMI (M ± SD)   Cut-off   Depressive symptom   Anxiety symptom
  ---- --------------------- ---------- ------------ -------------------- ------- ----------------- ----------- ---------------------- -------------- -------------- --------- -------------------- -----------------
  1    Astuti (2017)         ([@B44])   Indonesia    consecutive          168     Postnatal         No          No                     27.5 ± 5.5     NR             ≥5        NR                   NR
  2    Cui (2017)            ([@B45])   China        NR                   200     Perinatal         Yes         NR                     30.2 ± 3.9     NR             \>7       56.0                 NR
  3    Dorheim (2009)        ([@B46])   Norway       consecutive          2,830   Postnatal         No          NR                     30.0 ± 4.7     NR             \>5       16.6                 NR
  4    Francis (2017)        ([@B47])   USA          NR                   640     Both              No          NR                     27.0 ± 9.33    NR             ≥5        NR                   NR
  5    Fu (2012)             ([@B48])   China        stratified cluster   270     Perinatal         No          No                     NR             NR             ≥8        NR                   NR
  6    Gao (2012)            ([@B49])   China        random               128     Perinatal         NR          NR                     NR             NR             \>7       NR                   NR
  7    Gunduz (2016)         ([@B50])   Turkey       NR                   92      Perinatal         NR          NR                     30.4 ± 4.6     24.2 ± 3.2     \>5       NR                   NR
  8    Hairston (2016)       ([@B51])   Israel       NR                   152     Postnatal         NR          NR                     NR             NR             \>5       8.4                  NR
  9    Han (2015)            ([@B52])   China        NR                   147     Perinatal         No          Yes                    28.4 ± 4.0     NR             ≥8        NR                   NR
  10   Huang (2004)          ([@B53])   China (TW)   NR                   163     Postnatal         Yes         No                     30.0 ± 4.0     23.1 ± 2.6     ≥5        50.3                 NR
  11   Hung (2013)           ([@B54])   China (TW)   convenience          184     Perinatal         No          No                     NR             NR             \>5       NR                   NR
  12   Iranpour (2016)       ([@B55])   Iran         random               353     Postnatal         No          No                     27.0 ± 5.4     NR             ≥5        34.8                 NR
  13   Ko (2012)             ([@B56])   Korea        NR                   450     Both              NR          NR                     NR             NR             \>5       NR                   NR
  14   Ko (2014)             ([@B4])    China (TW)   NR                   327     Postnatal         No          NR                     30.7 ± 4.0     NR             \>5       NR                   NR
  15   Ko (2015)             ([@B57])   China (TW)   purposive            200     Perinatal         No          No                     31.4 ± 4.0     NR             ≥5        NR                   NR
  16   Li, Z (2018)          ([@B58])   China        NR                   288     Postnatal         NR          No                     NR             NR             ≥8        NR                   NR
  17   Li, P (2016)          ([@B59])   China        NR                   565     Perinatal         No          NR                     NR             NR             ≥11       25.1                 NR
  18   Luo (2016)            ([@B60])   China        NR                   260     Perinatal         Yes         NR                     30.2 ± 3.8     NR             ≥8        56.2                 NR
  19   Murphey (2017)        ([@B39])   USA          purposive            33      Postnatal         Yes         No                     22.3 ± 4.5     NR             \>5       NR                   NR
  20   Naghi (2011)          ([@B22])   Iran         consecutive          488     Perinatal         NR          NR                     25.8 ± 5.7     24.1 ± 1.7     \>5       NR                   NR
  21   Sut (2016)            ([@B61])   Turkey       NR                   152     Perinatal         No          NR                     NR             NR             \>5       NR                   NR
  22   Tobback (2017)        ([@B62])   Belgium      NR                   105     Postnatal         Yes         NR                     30.4 ± 4.5     NR             \>5       NR                   NR
  23   Tian (2018)           ([@B63])   China        cluster              535     Perinatal         NR          Yes                    28.0 ± 4.9     NR             ≥7        34.2                 NR
  24   Tsai (2011)           ([@B64])   China (TW)   convenience          30      Perinatal         Yes         No                     30.8 ± 4.7     24.6 ± 2.2     \>5       23.3                 NR
  25   Tsai (2016)           ([@B65])   China (TW)   convenience          274     Perinatal         NR          NR                     31.9 ± 4.0     21.1 ± 2.7     \>5       23.4                 NR
  26   Volkovich (2016)      ([@B66])   Israel       NR                   144     Perinatal         Yes         No                     29.0 ± 3.0     NR             \>5       NR                   NR
  27   Wang, G (2018)        ([@B67])   China        NR                   262     Perinatal         NR          No                     29.4 ± 3.2     26.3 ± 2.8     \>5       32.9                 NR
  28   Wang, H (2017)        ([@B68])   China        convenience          140     Perinatal         NR          No                     29.1 ± 2.9     NR             \>7       NR                   NR
  29   Wang, W (2017)        ([@B69])   China        convenience          129     Perinatal         No          No                     27.5 ± 4.2     NR             ≥5        NR                   NR
  30   Wang, Y (2010)        ([@B70])   China        NR                   74      Perinatal         NR          No                     26.8 ± 2.3     NR             \>5       NR                   NR
  31   Wen, S (2018)         ([@B14])   China (TW)   consecutive          160     Postnatal         No          No                     34.4 ± 3.5     NR             ≥5        NR                   NR
  32   Wu, X (2017)          ([@B71])   China        NR                   60      Perinatal         No          No                     27.6 ± 4.1     NR             ≥8        11.7                 18.3
  33   Wu, P (2017)          ([@B72])   China        NR                   137     Perinatal         NR          No                     NR             NR             ≥8        14.6                 19.7
  34   Yang, Y (2018)        ([@B73])   China        NR                   186     Perinatal         NR          NR                     NR             NR             \>5       39.9                 NR
  35   Yang, J (2006)        ([@B74])   China        NR                   126     Postnatal         No          No                     28.5 ± 4.0     NR             \>7       NR                   NR
  36   Zhang, W (2008)       ([@B75])   China        NR                   96      Perinatal         NR          No                     27.1 ± 2.6     NR             \>5       NR                   NR
  37   Zhang, Y (2018)       ([@B76])   China        NR                   1,000   Perinatal         Yes         NR                     30.3 ± 2.9     NR             \>7       50.3                 NR
  38   Zhang, L (2011)       ([@B77])   China        NR                   110     Perinatal         No          Yes                    29.2 ± 3.6     25.9 ± 2.9     ≥8        20                   NR
  39   Zhao, L (2018)        ([@B78])   China        NR                   200     Postnatal         No          NR                     27.4 ± 3.0     NR             \>7       20                   23.5
  40   Zhao, M (2017)        ([@B79])   China        convenience          182     Perinatal         NR          Yes                    NR             NR             \>7       57.3                 22.9
  41   Zheng (2011)          ([@B80])   China        random               354     Perinatal         Yes         No                     28.0 ± 3.5     25.3 ± 2.4     ≥8        26.7                 29.4
  42   Zhu (2018)            ([@B81])   China        NR                   198     Perinatal         NR          No                     29.4 ± 3.1     NR             \>5       17.7                 NR

M, mean; SD, standard deviation; No, Number; NR, Not report; BMI, body mass index; TW, Taiwan.

Prevalence of Poor Sleep Quality in Perinatal and Postnatal Women {#s3_2}
-----------------------------------------------------------------

The pooled prevalence of poor sleep quality based on the 42 studies was 54.2% (95% CI: 47.9--60.5%; *I* ^2^: 97.5%) as shown in [**Figure 2**](#f2){ref-type="fig"}, while the corresponding figure was 44.5% (95% CI: 37.6--51.6%; *I* ^2^: 96.4%) in perinatal women and 67.2% (95% CI: 57.6--75.5%; *I* ^2^: 96.5%) in postnatal women.

![Forest plot of prevalence of poor sleep quality.](fpsyt-11-00161-g002){#f2}

The Pooled PSQI Global and Component Score {#s3_3}
------------------------------------------

Based on the 28 studies with available data on total PSQI score and the 20 studies with PSQI component scores, the pooled PSQI total score was 7.54 ± 0.40 (95% CI of mean score: 6.75--8.33), while the average component scores of PSQI varied from 0.13 ± 0.04 (95% CI of mean score: 0.05--0.22) for use of sleeping medication to 1.51 ± 0.17 (95% CI of mean score: 0.82--1.48) for habitual sleep efficiency ([**Table 2**](#T2){ref-type="table"}).

###### 

Pooled PSQI global and component scores.

                               No. of studies   Point estimate   Standard error   Variance   95%CI
  ---------------------------- ---------------- ---------------- ---------------- ---------- ------------
  Sleep latency                20               1.23             0.11             0.01       1.00--1.45
  Sleep duration               20               0.99             0.19             0.04       0.61--1.36
  Sleep disturbances           20               1.38             0.06             \<0.01     1.26--1.49
  Daytime dysfunction          20               1.15             0.09             \<0.01     0.97--1.33
  Subjective sleep quality     20               1.48             0.07             \<0.01     1.35--1.61
  Habitual sleep efficiency    20               1.51             0.17             0.03       0.82--1.48
  Use of sleeping medication   14               0.13             0.04             \<0.01     0.05--0.22
  Total PSQI score             28               7.54             0.40             0.16       6.75--8.33

No, Number; CI, Confidence interval; PSQI, Pittsburgh Sleep Quality Index.

Subgroup and Meta-regression Analyses {#s3_4}
-------------------------------------

The results of subgroup analyses are presented in [**Table 3**](#T3){ref-type="table"}. Postnatal women reported higher poor sleep prevalence than perinatal women (67.2% and 44.5%, respectively, P \< 0.001). People in North America reported the highest prevalence of poor sleep quality (74.7%), followed by Asia (53.6%) and Europe (50.4%, P \< 0.001). Studies using multicenter design showed significantly higher prevalence than those using a single site design (65.4% and 46.6%, respectively, P = 0.01). Individuals with physical comorbidities reported lower prevalence of poor sleep quality than those without (28.6% and 60.1%, respectively, P \< 0.001). In addition, studies published before the year of 2016 reported significantly higher prevalence of poor sleep than those published in/after 2016 (64.7% and 47.7%, respectively, P = 0.01). Studies using lower cut-off values (i.e., ≥5) reported higher prevalence than those using high cut-offs (i.e., ≥11). Meta-regression analyses revealed that the prevalence of poor sleep quality was negatively associated with survey year (Slope = -0.079, P \< 0.001), but positively associated with maternal age (Slope = 0.005, P \< 0.001) and quality assessment score (Slope = 0.051, P \< 0.001) ([**Supplementary Figures 1--3**](#SM1){ref-type="supplementary-material"}).

###### 

Subgroup analyses of prevalence of poor sleep quality.

  Subgroups              Categories (No. of studies)   Prevalence (%)   95% CI       Sample size   Events   *I* ^2^ (%)   *P* value within subgroup   Q (*P* value across subgroups)
  ---------------------- ----------------------------- ---------------- ------------ ------------- -------- ------------- --------------------------- --------------------------------
  Continents             North America (2)             74.7             71.3--77.9   673           503      0.000         0.890                       37.668 **(\<0.001)**
  Asia (36)              53.6                          46.1--60.9       8,740        4,322         97.361   \<0.001                                   
  Europe (4)             50.4                          37.8--63.0       3,179        1,794         92.522   \<0.001                                   
  Study site             Multicenter (16)              65.4             53.7--75.5   7,616         3,746    97.904        \<0.001                     6.556 **(0.010)**
  Single site (23)       46.6                          38.3--55.0       4,418        2,587         97.452   \<0.001                                   
  Location               Urban (31)                    45.6             39.0--52.3   7,165         3,006    96.284        \<0.001                     9.517 **(0.009)**
  Rural (1)              44.6                          33.7--56.0       74           33            --       --                                        
  Mixed (3)              72.7                          56.8--84.3       3,638        2,251         97.851   \<0.001                                   
  Hospital type          General (24)                  51.8             43.3--60.1   8,061         4,317    97.500        \<0.001                     5.202 (0.074)
  Mixed (6)              62.5                          46.7--76.0       1,665        1,015         97.026   \<0.001                                   
  Specialized (5)        35.8                          21.8--52.7       1,730        559           97.478   \<0.001                                   
  Pregnancy              Both (2)                      92.2             42.9--99.5   1,090         919      98.459        \<0.001                     16.414 **(\<0.001)**
  Perinatal (28)         44.5                          37.6--51.6       6,597        2,761         96.403   \<0.001                                   
  Postnatal (12)         67.2                          57.6--75.5       4,905        2,939         96.464   \<0.001                                   
  Primipara              Yes (9)                       52.9             40.0--65.4   2,545         2,289    96.083        \<0.001                     0.399 (0.527)
  No (17)                58.0                          48.3--67.2       8,699        6,621         97.698   \<0.001                                   
  Comorbidity            Yes (4)                       28.6             20.6--38.2   1,019         974      87.158        \<0.001                     22.986 **(\<0.001)**
  No (21)                60.1                          52.1--67.5       4,408        3,569         94.912   \<0.001                                   
  BMI                    Normal (5)                    59.3             42.8--73.9   1,047         547      94.692        \<0.001                     3.459 (0.063)
  Overweight (3)         43.3                          39.7--46.9       726          314           0.000    0.723                                     
  Publication Year ^a^   Before 2016 (16)              64.7             54.8--73.5   5,977         3,643    97.252        \<0.001                     6.700 **(0.010)**
  In/After 2016 (26)     47.7                          39.6--55.9       6,615        2,976         97.460   \<0.001                                   
  Cut-off                \>5 (18)                      62.9             55.0--70.2   6,077         3,663    96.088        \<0.001                     168.506 **(\<0.001)**
                         ≥5 (7)                        77.9             65.9--86.5   2,378         1,431    96.117        \<0.001                     
                         \>7 (15)                      36.7             29.9--44.0   3,602         1,415    94.225        \<0.001                     
                         ≥7 (1)                        20.6             17.3--24.2   535           110      --            --                          
                         ≥11 (1)                       19.6             16.6--23.1   565           111      --            --                          

No, Number; BMI, body mass index; CI, Confidence interval; PSQI, Pittsburgh Sleep Quality Index; a: based on median split. Bolded values: \<0.05.

Study Quality Assessment, Sensitivity Analyses, and Publication Bias {#s3_5}
--------------------------------------------------------------------

The quality assessment scores ranged from 4 to 6 ([**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}). Most (81%) of the studies did not utilize random or consecutive sampling method, and around half (52%) did not report response rate, or the response rate was less than 70%. Sensitivity analysis did not find individual studies that could significantly change the overall primary results. The funnel plot and Begg\'s tests (P = 0.06) did not find publication bias ([**Supplementary Figure 4**](#SM1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

To our best knowledge, this was the first meta-analysis to examine the prevalence of poor sleep quality in perinatal and postpartum women and investigate its associated factors. The pooled prevalence (54.2%, 95% CI: 47.9--60.5%) of this meta-analysis was similar to the findings in pregnant women (45.7%, 95% CI: 36.5--55.2%) ([@B1]), but was higher than nonpregnant populations using the same sleep assessment tool, such as college students (24.1%, 95% CI: 21.0--27.5%) ([@B82]) and older adults (35.9%, 95% CI: 30.6--41.2%) ([@B83]).

Compared to nonpregnant women, those in perinatal and postpartum period are more likely to experience acute partial sleep deprivation and chronic sleep disruption, especially during labor and the first few days after giving birth ([@B84]). Commonly reported contributing factors of poor sleep quality included level of progesterone ([@B37]), physical discomforts ([@B85]), the infant\'s sleep--wake patterns, and the feeding practices ([@B86]).

Subgroup analyses revealed that the prevalence of poor sleep quality was higher in postnatal (67.2%, 95% CI: 57.6--75.5%) than in perinatal women (44.5%, 95% CI: 37.6--51.6%), which confirmed some ([@B47]), but not all studies ([@B87]--[@B89]). For instance, one longitudinal study using the PSQI found that 71% of women reported poor sleep in prenatal assessment and the figure increased to 77% during postpartum period ([@B47]). However, another longitudinal study found that women\'s sleep quality decreased progressively from their second to third trimester, but gradually improved during postnatal period ([@B87]). Studies using actigraphy and PSG also showed that even though mothers\' nighttime sleep deteriorates progressively throughout pregnancy and becomes poorest on the night before delivery, an improving trend further into the postpartum period was found ([@B88], [@B89]). Different study characteristics, socioeconomic contexts, and measurement tools could partly contribute to the different findings between studies.

As expected, use of lower PSQI cutoff values was associated with higher prevalence of poor sleep quality. The pooled PSQI total score in this meta-analysis was 7.54 ± 0.40 (95% CI of mean score: 6.75--8.33), which is consistent with the average PSQI score of 6.97 (95% CI of mean score: 5.30--6.85) throughout pregnancy reported previously ([@B1]). The lowest PSQI component score was 0.13 ± 0.04 (95% CI of mean score: 0.05--0.22) in the domain of "use of sleeping medication." It is possible that pregnant and postnatal women worry about the impact of medication side effects or potential risk on their infants; therefore, they are reluctant to receive medication treatment for sleep disturbances.

Studies conducted in America and those involving multicenter and mixed locations (rural and urban) tended to report higher prevalence of poor sleep quality. This could be partly attributed to the uneven number of studies across different subgroups; for example, only two studies were conducted in America, and only three studies included participants from both urban and rural areas. Women with physical comorbidities reported lower prevalence of poor sleep than those without. It is possible that while women with comorbidities were treated for their physical complaints, they received additional care/help for their sleep problems. Meta-regression analyses revealed a decreasing trend of poor sleep quality over time. With the increased attention on sleep in the past year, women in perinatal and postnatal period could have an easier access to sleep clinics and relevant health services.

In this meta-analysis, older maternal age was associated with higher prevalence of poor sleep quality, which is consistent with most earlier findings ([@B83], [@B90]). Traditionally, older women tended to have heavier domestic duties and care burden, and are more likely to experience physical discomforts and slower recovery from delivery ([@B85], [@B91]), all of which could increase the likelihood of poor sleep quality. However, Sedov et al. ([@B1]) suggested that in pregnant women, only gestational age, but not maternal age, was related to poor sleep quality.

Several limitations should be acknowledged in this meta-analysis. First, substantial heterogeneity, which is unavoidable in epidemiological studies ([@B92], [@B93]), still remained although subgroup and sensitivity analyses were performed. Second, some variables that may affect sleep quality, such as depression, economic status, marital status, and interpersonal relationship difficulties, were not investigated due to insufficient data in included studies. Third, the number of studies was relatively small in some subgroups. Finally, those with severe sleep problems, such as RLS and OSA, were not included in this meta-analysis. Sleep quality should be meta-analyzed separately in these populations.

Conclusions {#s5}
===========

In conclusion, this meta-analysis showed that poor sleep quality is common in perinatal and postnatal women. Given the negative impact of poor sleep quality on health outcomes and well-being, regular screening for poor sleep quality would be beneficial to improve sleep quality in this population.
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